Prostamax
Key Facts: Prostamax
- Category
- Bioregulators
- FDA Status
- Not FDA Approved
- Clinical Status
- Preclinical research, approved in Russia as supplement
- Administration
- Oral capsules or sublingual
- Typical Dose
- 10-20 mg daily
- Frequency
- Once or twice daily
- Duration
- 10-30 day cycles
Mechanism of Action
Prostamax is proposed to work the way the other ultrashort Khavinson peptides supposedly do: small enough to enter the cell nucleus and bind specific DNA sequences, shifting gene expression in prostate tissue toward a less inflamed, less age-degraded state. The hypothesis is tissue selectivity, so a prostate-derived peptide preferentially regulates prostate genes rather than acting on hormone receptors like a typical drug. This peptide-DNA targeting model is described in review papers but has not been independently validated for KEDP, so treat it as a proposed mechanism. There is no well-characterized receptor and no human pharmacology data establishing how a free tetrapeptide reaches and acts on prostate cells.
Research Summary
It is important to separate two things that get blurred together. The bovine prostate extract Prostatilen, sold in Russia as Vitaprost, has the bulk of the human clinical literature for chronic prostatitis and benign prostatic conditions. The synthetic single-sequence peptide Prostamax (KEDP) has far less of its own data, mostly Khavinson-school animal and cell-culture work reporting reduced prostate inflammation and slowed pathological remodeling in rat prostatitis models. There are no Western randomized controlled trials of synthetic KEDP, and no independent replication of its specific effects outside the originating institute. The chromatin and gene-expression claims rest on the broader Khavinson peptide framework rather than direct human prostate trials. Bottom line: plausible preclinical signal, a real parent-extract track record that does not automatically transfer to the synthetic peptide, and no rigorous human efficacy data for Prostamax itself.
Dosing Information
Note: Animal study doses may not translate directly to humans.
Typical Dosingⓘ
Community experience
10-20 mg daily
10-20 mg daily
Once or twice daily
Prostate bioregulator. Khavinson peptide for prostate health.
Research Dosingⓘ
Scientific studies
Doses from bioregulator supplement protocols
Doses from Studies
10-20 mg daily
Duration
10-30 day cycles
Administration
Oral capsules or sublingual
Timing & Administration
Best Time to Take
Morning on empty stomach
Once or twice daily
Food Recommendation
Take on empty stomach
Why This Timing?
Peptide bioregulators typically taken fasted for optimal absorption
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Generally well-tolerated
- ●Limited safety data outside Russia
- ●Not FDA approved
References
- https://pubmed.ncbi.nlm.nih.gov/11713572/
- https://www.mdpi.com/1420-3049/26/22/7053
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9032300/
- https://link.springer.com/article/10.1134/S2079057013030065
Research This Peptide Further
Frequently Asked Questions
What does Prostamax do?
Prostamax is a synthetic Khavinson tetrapeptide (Lys-Glu-Asp-Pro, KEDP) marketed as a prostate bioregulator, conceived as the defined-sequence successor to the older bovine prostate extracts Prostatilen and Vitaprost. It is studied for prostate inflammation and age-related prostate changes, and it has no FDA or EMA approval. Most of the actual clinical prostate evidence belongs to the parent extract, not to the synthetic KEDP peptide itself.
How does Prostamax work?
Prostamax is proposed to work the way the other ultrashort Khavinson peptides supposedly do: small enough to enter the cell nucleus and bind specific DNA sequences, shifting gene expression in prostate tissue toward a less inflamed, less age-degraded state. The hypothesis is tissue selectivity, so a prostate-derived peptide preferentially regulates prostate genes rather than acting on hormone receptors like a typical drug. This peptide-DNA targeting model is described in review papers but has not been independently validated for KEDP, so treat it as a proposed mechanism. There is no well-characterized receptor and no human pharmacology data establishing how a free tetrapeptide reaches and acts on prostate cells.
Is Prostamax FDA approved?
No, Prostamax is not currently FDA approved. Current status: Preclinical research, approved in Russia as supplement
What are the side effects of Prostamax?
Reported side effects include: Generally well-tolerated, Limited safety data outside Russia, Not FDA approved. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Prostamax?
Community-reported common dose: 10-20 mg daily (Once or twice daily). Range: 10-20 mg daily. Administration: Oral capsules or sublingual. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Prostamax or used in similar applications.
Livagen
PreclinicalLivagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, or KEDA) from the family of short "peptide bioregulators" developed by Vladimir Khavinson's group in St. Petersburg, marketed in connection with liver and immune function. The proposed appeal is epigenetic: it has been reported to loosen tightly packed chromatin in aged cells, supposedly switching age-silenced genes back on. Evidence is limited to small laboratory and cell studies, mostly from one research group, with no clinical trials, so claims should be read with heavy skepticism.
BioregulatorsOvagen
PreclinicalOvagen is a synthetic ultra-short peptide, marketed as the tripeptide Glu-Asp-Leu (EDL), and grouped with the Khavinson-style "peptide bioregulators" promoted for liver and gastrointestinal support. Like its cousins in that family, it is claimed to act at the gene-expression level in a tissue-specific way. The honest picture: there is very little verifiable scientific data on Ovagen specifically, no clinical trials, and most of what is written about it comes from vendors rather than peer-reviewed research.
BioregulatorsCortagen
PreclinicalCortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro, AEDP) from Vladimir Khavinson's Russian peptide bioregulator program, designed as the defined-sequence stand-in for Cortexin, an older cattle brain cortex extract used in Russian neurology. It is studied mostly for nerve repair, brain function and aging, and it is not approved by the FDA or EMA. Real evidence is limited to animal experiments and Russian-institute work, with no Western randomized human trials.
BioregulatorsVesugen
PreclinicalVesugen is a synthetic tripeptide (Lys-Glu-Asp, or KED) from the Khavinson family of short peptide bioregulators, studied for vascular and neuroprotective effects. It is a research compound, not an approved drug, with no registered human clinical trials.
BioregulatorsChonluten
PreclinicalChonluten is a synthetic tripeptide (Glu-Asp-Gly, EDG) from the Khavinson bioregulator family, pitched as the lung and bronchial peptide, derived conceptually from the same program that produced Epitalon and Cortagen. It is researched for respiratory tissue and age-related lung decline, and it has no FDA or EMA approval. The evidence is essentially all preclinical or uncontrolled Russian clinical observation, with no randomized human trials.
BioregulatorsCrystagen
PreclinicalCrystagen is a synthetic tripeptide (Glu-Asp-Pro, or EDP) from the Khavinson family of short peptide bioregulators, studied as an immune and thymic regulator. It is a research compound, not an approved drug, with no registered human clinical trials. Note: many vendor pages list the wrong sequence; the correct one is Glu-Asp-Pro (EDP).
BioregulatorsWant updates on Prostamax research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.